Catalysts / ALLO
Upcoming FDA decisions and readouts we track for Allogene Therapeutics, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for Allogene Therapeutics (ALLO, listed on Nasdaq). They cover 2 programmes: ALLO-329 (Autoimmune disease (allogeneic CD19/CD70 CAR-T)) and Cemacabtagene ansegedleucel (First-line large B-cell lymphoma consolidation).
First on the list: the Phase 1 readout for ALLO-329 (Autoimmune disease (allogeneic CD19/CD70 CAR-T)), guided by the company to Q4 2026. By stage, the upcoming rows are 1 Phase 1 readout and 1 Phase 2 readout.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Allogene Therapeutics ALLO · Nasdaq | ALLO-329 | Autoimmune disease (allogeneic CD19/CD70 CAR-T) | Q4 2026 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Allogene Therapeutics ALLO · Nasdaq | Cemacabtagene ansegedleucel | First-line large B-cell lymphoma consolidation | Mid 2027 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList